Transcripts

ADMA Biologics (ADMA) earnings call transcripts

Earnings call transcripts for ADMA Biologics, Inc., with a summary, the guidance given, and what analysts pressed on.

  • Q2 2026 earnings call

    Management portrayed accelerating Asceniv utilization and stabilizing Bivigam demand as evidence that mix shift can offset standard IG pressure.

    Aug 05, 2026Confident0.82